December 2019—T2 Biosystems announced that its T2Resistance Panel is available as a research use only test in the United States. The panel is expected to receive the CE mark by the end of 2019.
In a separate release, T2 Biosystems and CARB-X, a worldwide nonprofit partnership dedicated to accelerating the development of novel antibiotics and other approaches to address the threat of drug-resistant bacteria, announced that the T2Resistance Panel is the first diagnostic to graduate from CARB-X’s portfolio of projects.
Pages: 1 2